Investor Relations

Investor Relations

Corporate Profile

Allena is a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.